For more than a decade, artificial intelligence has been touted as a way to dramatically accelerate drug discovery. Yet despite billions of dollars in investment, relatively few AI-designed medicines have made it to patients. That’s partially because the timelines for careful drug testing can’t be…
Thank you for reading this post, don't forget to subscribe!
Source: IEEE Spectrum
Automatically aggregated summary — full article and all rights belong to the original publisher.